Scholarlink

<p>Cefiderocol (FDC), a siderophore cephalosporin, shows potent activity against difficult-to-treat <i>Pseudomonas aeruginosa</i>. We analyzed 25 clinical KPC-variant-producing <i>P. aeruginosa</i> from China (2016-2025) and laboratory-induced FDC-resistant strains (KPC-2/ST463, a high-risk <i>P. aeruginosa</i> clone in China), using WGS, RNA-seq, RT-qPCR, metabolomics, and QM/MM simulations. Clinical isolates were dominated by KPC-33/ST463, highly resistant to ceftazidime-avibactam (25/25) but largely FDC-susceptible (22/25). FDC-induced strains acquired <i>bla</i><sub>KPC-33</sub> mutations and siderophore receptor disruptions. QM/MM metadynamics revealed that KPC-33 optimized Ser70 catalytic-site dynamics, reducing the hydrolysis free energy barrier (<i>ΔG</i><sub><i>‡</i></sub> from 15.2 to 13.0 kcal/mol) and increasing catalytic efficiency (<i>kcat/K</i><sub><i>M</i></sub> from 50 to 2000 M⁻¹s⁻¹). The difference in binding pockets between receptor and ligand required the Ser70 hydroxyl oxygen atom of KPC-2 to travel longer distances to complete nucleophilic attack and acylation. We observed a bifurcated response to antibiotic pressure: clinical adaptation involved multi-scale regulatory shifts in iron uptake and efflux, whereas laboratory induction triggered acute genetic transitions in primary resistance determinants. Global epidemiology shows widespread KPC-plasmid dissemination, particularly in Asia. Monitoring plasmid backbones, Ω-loop KPC variants, and siderophore receptor status may guide FDC therapy and anticipate resistance in high-risk strains.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mechanistic and evolutionary determinants of cefiderocol resistance in KPC-producing Pseudomonas aeruginosa

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月24日

查看全文
  • Wenhao Wu,
  • Xi Li,
  • Longjie Zhou,
  • Haiyang Liu,
  • Weixiao Shi,
  • Piaopiao Zhang,
  • Yunsong Yu,
  • Tingting Qu

摘要

Cefiderocol (FDC), a siderophore cephalosporin, shows potent activity against difficult-to-treat Pseudomonas aeruginosa. We analyzed 25 clinical KPC-variant-producing P. aeruginosa from China (2016-2025) and laboratory-induced FDC-resistant strains (KPC-2/ST463, a high-risk P. aeruginosa clone in China), using WGS, RNA-seq, RT-qPCR, metabolomics, and QM/MM simulations. Clinical isolates were dominated by KPC-33/ST463, highly resistant to ceftazidime-avibactam (25/25) but largely FDC-susceptible (22/25). FDC-induced strains acquired blaKPC-33 mutations and siderophore receptor disruptions. QM/MM metadynamics revealed that KPC-33 optimized Ser70 catalytic-site dynamics, reducing the hydrolysis free energy barrier (ΔG‡ from 15.2 to 13.0 kcal/mol) and increasing catalytic efficiency (kcat/KM from 50 to 2000 M⁻¹s⁻¹). The difference in binding pockets between receptor and ligand required the Ser70 hydroxyl oxygen atom of KPC-2 to travel longer distances to complete nucleophilic attack and acylation. We observed a bifurcated response to antibiotic pressure: clinical adaptation involved multi-scale regulatory shifts in iron uptake and efflux, whereas laboratory induction triggered acute genetic transitions in primary resistance determinants. Global epidemiology shows widespread KPC-plasmid dissemination, particularly in Asia. Monitoring plasmid backbones, Ω-loop KPC variants, and siderophore receptor status may guide FDC therapy and anticipate resistance in high-risk strains.